Clinical Trials

A Phase II Randomized Study of Adjuvant vs. Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma.


Study ID
SWOG S1801

NCT Number
NCT03698019 (Click on the NCT number for more information about the trial)

Research Study Number
2018-1051

Principle Investigator
Dr. Andrew Pecora

Phase
II

Sponsor
SWOG


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now